If you were harmed by a prescription drug or medical device and you’re wondering why the manufacturer seems to be pointing fingers at your doctor — and your doctor seems to be pointing fingers at the manufacturer — you’ve likely stumbled into one of the most consequential legal doctrines in pharmaceutical litigation: the learned intermediary doctrine. In 2026, this doctrine is reshaping thousands of injury claims, most visibly in the exploding Ozempic and GLP-1 mass-tort litigation involving over 4,200 pending lawsuits. Understanding how it works, where it breaks down, and how it directly affects the dollar value of your claim is no longer just a matter for lawyers — it’s essential knowledge for every injured patient.
What Is the Learned Intermediary Doctrine in Medical Malpractice?
The learned intermediary doctrine medical malpractice defense is a liability-shifting rule that allows prescription drug and medical device manufacturers to discharge their duty to warn patients by instead warning the prescribing physician. The theory is that a physician — as a trained medical professional — acts as a “learned intermediary” between the manufacturer and the patient, evaluating risks and personalizing warnings for the specific patient’s situation. The term was first used in Sterling Drug v. Cornish (8th Cir. 1966), and the doctrine has since spread to every corner of American law.
The reach of this doctrine is staggering. As confirmed by the Legal Information Institute at Cornell Law School, the Washington Supreme Court has acknowledged that every state in the country, along with Washington D.C. and Puerto Rico, has adopted the learned intermediary doctrine in some form. That means no matter where your injury occurred, this doctrine is almost certainly relevant to your case.
The core rationale rests on two assumptions: first, that physicians are better positioned than patients to evaluate complex pharmacological risk profiles; and second, that doctors can tailor warnings to individual patient circumstances in ways that a generic label cannot. These assumptions, as we’ll explore, are increasingly contested in an era of direct-to-consumer pharmaceutical advertising and mass-tort litigation.
How the Doctrine Divides Fault Between Manufacturers and Physicians
The mechanical operation of the learned intermediary doctrine medical malpractice framework creates a clean but often brutal division of liability. When a manufacturer provides an adequate warning to the prescribing physician, that manufacturer is generally shielded from failure-to-warn claims — even if the patient never received that information. When the warning to the physician is inadequate, the manufacturer faces direct liability. But when the manufacturer’s warning was technically adequate and the physician simply failed to pass it along to the patient, liability can shift entirely to the prescribing physician, who may face a separate medical malpractice claim.
This creates a situation where injured patients may need to pursue two fundamentally different defendants under two different legal theories simultaneously. To understand how this blame allocation affects your potential compensation, tools like a mass tort settlement calculator can help you model different liability scenarios and estimate what your claim might be worth depending on which party the evidence ultimately points toward.
Off-label prescribing adds yet another layer of complexity. When a physician prescribes a drug for a use the FDA has not approved, a separate medical malpractice cause of action against that prescribing doctor may arise, entirely distinct from any product liability claim against the manufacturer. This is particularly significant in the GLP-1 litigation, where some patients were prescribed semaglutide for weight loss or other indications outside the originally approved scope.
The 2026 Dearinger v. Eli Lilly Ruling: A Critical Boundary
The most significant 2026 development in learned intermediary doctrine medical malpractice jurisprudence is the Ninth Circuit’s decision in Dearinger v. Eli Lilly, which affirmed summary judgment in favor of Lilly. The court drew a sharp line: the manufacturer’s duty to warn does not extend to non-prescribing treating physicians. Only the prescribing physician qualifies as the learned intermediary. This matters enormously because many patients see multiple doctors — specialists, hospitalists, urgent care providers — who may have recognized a drug’s danger but were not the ones who wrote the original prescription.
The Dearinger court further held that a prescribing physician’s testimony that he would have prescribed the drug regardless of any additional warning is sufficient to break the causation chain. Even if a manufacturer’s warning was deficient, the plaintiff cannot recover if the prescribing doctor says the warning wouldn’t have changed his decision. This “prescribe anyway” testimony has become a powerful tool for manufacturers seeking to escape liability at the summary judgment stage.
At the pleadings stage, the doctrine can be equally devastating. In McCrackin v. Rex Medical (N.D. Ala., January 8, 2026), a federal court dismissed failure-to-warn claims with prejudice under the learned intermediary doctrine before the case even reached discovery — demonstrating that this is not merely a trial defense but a threshold barrier that can eliminate claims entirely in their earliest stages.
The GLP-1 and Ozempic MDL: Learned Intermediary Doctrine at Scale
Nowhere is the learned intermediary doctrine medical malpractice conflict more visible in 2026 than in the two active multidistrict litigations involving GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide. MDL 3094 covers gastroparesis claims, and MDL 3163 addresses NAION (non-arteritic anterior ischemic optic neuropathy) vision loss claims. Both MDLs are before Judge Karen Marston in the Eastern District of Pennsylvania, and together they involve more than 4,200 pending lawsuits as of 2026.
Novo Nordisk has invoked the learned intermediary doctrine as its primary shield in this litigation, arguing that it adequately warned prescribing physicians of the relevant risks and that those physicians bear responsibility for communicating those risks to patients. The core failure-to-warn theory advanced by plaintiffs, however, is that manufacturers knew or should have known about serious risks — including severe gastroparesis and permanent vision loss — and failed to adequately disclose them even to physicians. Judge Marston allowed 12 of 17 counts to proceed, including the core failure-to-warn claims, and rejected the manufacturers’ broad federal preemption defense.
The FDA dealt a significant blow to Novo Nordisk’s credibility in March 2026, issuing a formal warning letter citing the company’s failure to report serious adverse events within required regulatory deadlines. This failure to timely report adverse events to the FDA undermines the manufacturer’s argument that it fully and adequately warned the medical community — a critical weakness in its learned intermediary defense. Patients pursuing these claims should use a mass tort settlement calculator to understand how this evidentiary development could affect individual claim values across the MDL.
The Choice-of-Law Problem in Nationwide MDLs
A 2026 UMKC Law Review analysis identified a structural complication that makes GLP-1 learned intermediary litigation particularly complex: because the MDL aggregates claims from plaintiffs across all 50 states, no single state’s failure-to-warn doctrine automatically governs. Each plaintiff’s claim may be subject to a different state’s version of the learned intermediary doctrine, with different exceptions, different causation standards, and different attitudes toward direct-to-consumer advertising. This patchwork creates enormous variability in claim value and litigation strategy depending on where each plaintiff was prescribed and took the drug.
Exceptions That Can Restore Manufacturer Liability
The learned intermediary doctrine medical malpractice defense is not absolute. Two major exceptions can pierce the manufacturer’s shield and restore direct liability to the drug or device maker, potentially transforming the landscape of patient recovery.
The Direct-to-Consumer Advertising Exception
The most hotly contested exception involves direct-to-consumer (DTC) pharmaceutical advertising. The argument is intuitive: when a manufacturer bypasses the physician entirely and markets its drug directly to patients through television commercials, social media campaigns, and print advertising, it can no longer claim it relies solely on the physician as the conduit for risk communication. New Jersey’s Supreme Court articulated this principle most clearly in Perez v. Wyeth (1999), holding that DTC advertising creates a direct duty to warn consumers.
West Virginia has also historically recognized the DTC exception. However, the majority of states — including Washington, which analyzed the issue carefully — have rejected it, reasoning that DTC advertising does not change the physician’s fundamental role in individualizing warnings for specific patients. This split creates significant strategic variation across the GLP-1 MDL: a plaintiff from New Jersey whose injury arises from a drug heavily promoted through DTC campaigns may have a manufacturer liability theory that a plaintiff from Washington does not.
The GLP-1 drugs have been among the most aggressively advertised pharmaceuticals in recent American history, making the DTC exception argument particularly relevant. Plaintiffs’ attorneys are already arguing that the saturation-level marketing of semaglutide directly to consumers, encouraging them to “ask their doctor,” warrants application of the DTC exception even in states that have not yet formally adopted it.
The FDA-Mandated Patient Warning Exception
The second major exception arises when federal law requires that warnings go directly to patients rather than solely to physicians. When the FDA mandates patient package inserts or medication guides, a manufacturer cannot credibly claim it discharged its duty by warning only the doctor. The FDA-required patient warning is itself evidence that the regulatory framework recognizes patients as independent recipients of risk information — not merely passive subjects to be warned through their physicians. In cases involving mandatory medication guides, the learned intermediary doctrine may be entirely inapplicable to the warnings covered by those guides.
How Blame Allocation Directly Affects Your Settlement Value
Understanding the learned intermediary doctrine medical malpractice framework is not merely academic — it has direct, measurable consequences for injured patients seeking compensation. The following table illustrates how different liability configurations produce dramatically different recovery scenarios:
| Liability Scenario | Primary Defendant | Insurance Coverage Type | Typical Recovery Pool | Key Legal Hurdle |
|---|---|---|---|---|
| Manufacturer warning inadequate; LID fails | Drug/device manufacturer | Product liability (corporate) | Highest — large corporate defendants | Proving warning inadequacy to physician |
| Manufacturer warning adequate; physician failed to warn patient | Prescribing physician | Medical malpractice insurance | Moderate — capped by policy limits | Proving physician breach of duty |
| DTC exception applies (NJ/WV) | Manufacturer + physician (both) | Both product liability and malpractice | Highest — dual defendant recovery | Proving DTC advertising reached patient |
| Off-label prescribing by physician | Prescribing physician (separate claim) | Medical malpractice insurance | Moderate — separate cause of action | Proving off-label use was negligent |
| MDL bellwether verdict (GLP-1) | Manufacturer (primarily) | Corporate product liability | Variable — depends on bellwether outcomes | Causation and LID exceptions |
When fatal harm results from these liability failures — for example, a wrongful death caused by a manufacturer’s failure to disclose a lethal cardiac risk — the recovery calculation becomes even more complex. Families navigating those claims can use a wrongful death calculator to begin quantifying economic and non-economic damages across different liability scenarios before consulting with qualified legal counsel.
The practical takeaway is this: whether the learned intermediary doctrine shields the manufacturer or collapses under one of its exceptions determines not just who pays, but how much total compensation is available. Manufacturer defendants typically have far larger liability exposure than individual physicians whose malpractice coverage is capped by policy limits. Getting the liability allocation right can mean the difference between a modest settlement and full compensation for life-altering injuries.
What Injured Patients Should Know in 2026
The learned intermediary doctrine medical malpractice landscape in 2026 is at a genuine inflection point. The Dearinger ruling tightens the doctrine’s application and makes causation harder to prove against manufacturers when prescribing physicians claim they would have prescribed regardless. The GLP-1 MDL, with its FDA adverse-event reporting failures and aggressive DTC advertising history, is testing the doctrine’s limits in real time before Judge Marston. And the choice-of-law complexity identified in the 2026 UMKC Law Review analysis means that where you received your prescription may matter as much as what the manufacturer knew.
For patients injured by prescription drugs or devices who are trying to understand where the learned intermediary doctrine medical malpractice framework places them in the liability chain, early legal evaluation is critical. The doctrine is not a wall — it is a gate with exceptions, and whether those exceptions apply to your specific facts depends on your state, your prescribing physician’s conduct, the nature of the manufacturer’s advertising, and what the FDA required in terms of patient-directed warnings.
To understand how the learned intermediary doctrine and liability allocation might affect the value of a personal injury claim arising from pharmaceutical harm, you can begin with a personal injury settlement calculator as a starting point — recognizing that actual claim values depend on jurisdiction-specific rules, the strength of expert testimony, and how courts in 2026 continue to develop these rapidly evolving legal standards.
Frequently Asked Questions About the Learned Intermediary Doctrine
What is the learned intermediary doctrine in simple terms?
The learned intermediary doctrine is a legal rule that says a drug or device manufacturer can fulfill its duty to warn patients about risks by instead warning the prescribing physician. The physician — as a trained medical professional — is then responsible for relaying those risks to the patient. If the manufacturer warned the doctor adequately and the doctor failed to warn the patient, the manufacturer may be off the hook while the doctor faces potential medical malpractice liability.
Does the learned intermediary doctrine apply in every state?
Yes. As of 2026, every U.S. state, Washington D.C., and Puerto Rico has adopted some version of the learned intermediary doctrine. However, the doctrine’s scope, its exceptions, and how courts apply it vary significantly from state to state. New Jersey and West Virginia, for example, recognize a direct-to-consumer advertising exception that most other states do not, meaning manufacturer liability is easier to establish in those jurisdictions when aggressive consumer-facing advertising was involved.
How does the Dearinger v. Eli Lilly ruling in 2026 affect my drug injury claim?
The 2026 Ninth Circuit decision in Dearinger v. Eli Lilly established two important limits for plaintiffs. First, the manufacturer’s duty to warn only runs to the prescribing physician — not to other treating physicians who may have seen you during your care. Second, if the prescribing physician testifies that he or she would have prescribed the drug even with a stronger warning, that testimony can break the causation chain and defeat your failure-to-warn claim against the manufacturer entirely, even if the warning was inadequate.
Can I sue both the drug manufacturer and my doctor under the learned intermediary doctrine framework?
Yes, in many cases. If the manufacturer’s warning to your physician was inadequate, you may have a product liability claim against the manufacturer. If the warning to your physician was technically adequate but your physician failed to pass that information to you, you may have a separate medical malpractice claim against your physician. In states recognizing the DTC advertising exception, you may be able to pursue the manufacturer directly even when it warns physicians. Off-label prescribing creates yet another potential malpractice theory against the prescribing doctor that exists independently of product liability.
How does the learned intermediary doctrine affect GLP-1 and Ozempic lawsuits in 2026?
Novo Nordisk is using the learned intermediary doctrine as its primary defense in the two active GLP-1 MDLs involving over 4,200 plaintiffs before Judge Karen Marston in the Eastern District of Pennsylvania. The company argues it adequately warned prescribing physicians of risks like gastroparesis and vision loss. Plaintiffs counter that the warnings were inadequate and that Novo Nordisk’s failure to timely report adverse events to the FDA — as cited in a March 2026 FDA warning letter — undermines the adequacy of any physician warnings. Judge Marston allowed core failure-to-warn claims to proceed, keeping the litigation alive despite the doctrine’s invocation.
Legal disclaimer: This article is for general informational and educational purposes only and does not constitute legal advice; no attorney-client relationship is created by reading this content, and you should consult a licensed attorney in your jurisdiction for advice specific to your situation.
Related reading: $1.92 Million Verdict: How Wrongful Death Damages Are Calculated When A Laboratory Fails To Report A Critical Test Result In Time
Related reading: $0 Vs. Full Recovery: How The Loss Of Chance Doctrine Changes Every Number In A Wrongful Death Damages Calculation When The Victim Was Already Sick
Christine Norwood is a medical malpractice research analyst with a background in healthcare quality and medical-legal analysis. She specializes in helping patients and families understand their rights when harmed by medical negligence. Ms. Norwood is not a physician or attorney and the information provided is for educational purposes only.